Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. - Hortobagyi, G. N.; Stemmer, S. M.; Burris, H. A.; Yap, Y.-S.; Sonke, G. S.; Paluch-Shimon, S.; Campone, M.; Blackwell, K. L.; André, F.; Winer, E. P.; Janni, W.; Verma, S.; et al. (New England Journal of Medicine, 2016)